What Centellase Treats: Main Uses and Benefits

Centellase is commonly used as a vascular protectant and dermatological agent applied across domains where additional symptomatic support is needed. Its therapeutic components are traditionally used for conditions including chronic venous insufficiency and ulcers.

The medication helps address symptom clusters that may become intense, such as the lower limb heaviness, painful sensations, and oedema (swelling) associated with Chronic Venous Insufficiency (CVI). It is also relevant for managing structural challenges, specifically applied in addressing non-healing wounds, certain trophic lesions, and the development of hypertrophic scars or keloids following surgical intervention or trauma.

The core benefit is providing support that helps ease the overall symptom burden, supporting the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort.

“A core therapeutic focus is to provide supportive relief for symptoms that interfere with daily functioning and assist with maintaining stability.”

---

Quick Fact: Relief for Leg Heaviness Centellase is commonly used to help manage the sensation of heavy and painful legs by supporting microcirculatory function and contributing to the reduction of associated swelling.

Regulatory References

1. NIH LiverTox overview on Centella asiatica

Who Can and Cannot Use Centellase?

Official regulatory documentation strictly defines the eligible population for Centellase based on established safety criteria and the availability of clinical data. This eligibility profile is categorized by absolute prohibitions, age constraints, and physiological restrictions.

The medicine is formally contraindicated in individuals with known hypersensitivity (allergy) to the active substance, Centella asiatica, or to any plants belonging to the Apiaceae (Umbelliferae) family.

Population	Regulatory Status	Basis of Classification
Adults (18+ years)	Eligible	Established traditional use when contraindications are absent.
Children/Adolescents (<18)	Not Recommended	Safety has not been established due to a lack of adequate data.
Pregnant/Breastfeeding	Not Recommended	Safety has not been established due to insufficient data.

Consequently, the medicine is not recommended for children and adolescents under 18 years of age because safety has not been established. Similarly, its use is not recommended during pregnancy or lactation. These restrictions define the permitted population as adults who are neither pregnant nor breastfeeding and have no documented allergies to the active constituents. The official label does not include formal restrictions regarding severe renal or hepatic impairment.

Interactions with other medicines and products

Official government regulatory documentation for the authorized Centellase product, which contains an extract of Centella asiatica, establishes a minimal interaction profile for the drug. The regulatory assessment explicitly states that no interactions are known with other medicinal products or other forms of interaction based on the current body of evidence. This defining characteristic structures the entire regulatory interaction section.

Official Interaction Profile Summary

The most definitive statement from authoritative sources is the lack of documented clinical or pharmacokinetic interactions, meaning no formal restrictions are imposed regarding co-administration with prescription or non-prescription medicines.

Interaction Scope	Regulatory Status
Medicinal Product Categories	None listed; no known interactions documented.
Specific Interacting Medicines	None explicitly identified in regulatory documents.
Mechanistic Basis of Interactions	Not applicable; the lack of known interactions precludes listing specific enzyme (e.g., CYP450) or transporter (e.g., P-gp) effects in the interaction section.
Timing or Separation Rules	None required due to the absence of known interactions.
Population-Specific Notes	No specific interaction considerations are documented for subpopulations (e.g., renal impairment, elderly).

This official statement establishes that, according to the available clinical data assessed by regulatory bodies, the product is not associated with known constraints on its co-administration with other agents.

Centellase, composed of the triterpenoid saponins asiaticoside and madecassoside, exerts its primary pharmacological action on the extracellular matrix (ECM) and cellular signaling within connective tissues. These pentacyclic triterpenes interact with dermal fibroblasts to modulate their proliferative activity and the synthesis of structural proteins. Specifically, asiaticoside induces the production of Type I collagen by activating the TGF-beta/Smad signaling pathway. This pathway involves the phosphorylation of Smad 2 and Smad 3, promoting their association with Smad 4, which collectively enhances gene transcription for Type I collagen.

Madecassoside contributes by intervening in inflammatory cascades. It acts as an inhibitor of Nuclear Factor-kappa B (NF-kappaB) nuclear translocation and activity, which subsequently suppresses the expression and release of pro-inflammatory cytokines such as TNF-alpha and IL-1beta. This modulation of NF-kappaB signaling restricts the initial and persistent phases of tissue response. The combined effect involves increasing the deposition and organization of Type I collagen and fibronectin, while simultaneously dampening localized inflammatory processes, leading to the physiological consequence of tissue remodeling and enhanced structural integrity.

How Centellase is Used: Official Administration Guidelines

Centellase, which is based on the Total Triterpenoid Fraction of Centella asiatica (TTFCA), is used according to specific administration instructions. These guidelines define the approved routes, dosage ranges, and conditions for use, ensuring a standardized approach in clinical practice.

---

Official Routes and Forms of Administration

The standardized extract is officially administered via two primary routes. Systemic use relies on oral tablets, which contain a specified strength, such as 30 mg of the triterpenoid fraction. For localized applications, topical preparations, including creams and ointments, are also available in some regions, targeting dermatological needs.

---

Standard Dosage and Timing

For the oral form, the dosage regimen is generally defined as 30 mg to 60 mg daily for adults, corresponding to one or two 30 mg tablets. This dosage is typically administered once or twice a day.

Timing: A key instruction for the oral tablets is that they are preferably taken at mealtimes (with food). The tablets are designed to be swallowed whole with water.

---

Use Duration and Population Rules

Duration: The official protocol specifies that Centellase is intended for a short period of treatment. It is not designated as a medication for chronic, indefinite maintenance.

Population: Use in children and adolescents under 18 years of age is not supported by established safety and efficacy data. Standard guidelines do not provide instructions for dose modification in cases of renal or hepatic impairment.

Research evidence / Overview of studies for Centellase

Evidence for use in Chronic Venous Insufficiency (CVI)

Research involving Centellase was conducted in settings exploring conditions characterized by symptoms such as pain, tingling, and heaviness in the legs. Researchers primarily used short-term Randomized Controlled Trials (RCTs) and subsequently summarized their results in systematic reviews and meta-analyses. These trials focused on adult populations who met criteria for venous discomfort.

The studies research examined patient-reported outcomes describing perceived discomfort and leg sensation. Additionally, research explored objective measurements of microcirculatory parameters, such as the rate of ankle swelling and specific indices of blood flow in the smallest vessels. Data show patterns related to symptom intensity and physiological changes were monitored within the defined time intervals of the trials.

Evidence for use in Wound and Scar Management

Research involving the extract was conducted in clinical settings exploring outcomes such as healing, re-epithelialization, and scar characteristics following injury. Research included RCTs and systematic reviews focusing on both oral and topical formulations. Studies explored populations with diverse dermatological concerns, including post-surgical wounds, thermal burns, and established scars.

Outcomes related to physical discomfort and the healing process was studied for in these trials. Key limitations included modest sample sizes in individual trials, alongside high data heterogeneity across the types of injuries studied and the specific product forms used. The research base is often characterized as having an evidence quality level of Moderate to Low due to these constraints.

Long-term Studies and Follow-up

Research focusing on Centellase has primarily examined patient responses over short, defined time intervals. For CVI, the typical follow-up durations were limited, generally ranging from a few weeks up to 12 weeks in the primary efficacy studies. Long-term outcomes are not well characterized based on the currently reviewed regulatory evidence. There is limited information for long-term outcomes beyond the trial period, specifically concerning extended observation of microcirculation parameters or symptom patterns over many months or years.

Evidence Quality and Research Gaps

Overall, the research for Centellase contributes to the broader evidence landscape, but the certainty remains low in some key areas. Analyses of the research often point out that evidence quality varies across studies, with methodological issues like incomplete reporting affecting the confidence in some pooled results. Comparative evidence is lacking in some areas, meaning direct comparisons to other established treatments are not always available across the range of indications. Evidence highlights what is known — and what is still uncertain — about the effects measured during the studied period.

Key Studies & References

1. A Systematic Review of Randomized Controlled Trial on Efficacy of Centella asiatica for Wound Healing

Common questions about Centellase (FAQ)

Q: What is Centellase and what is it used for?

A: Centellase is a medication containing purified extracts of the Centella asiatica plant, also known as Gotu Kola. It is often used to assist in the healing of skin and soft tissue injuries, such as minor burns, wounds, and skin grafts. It is also used to improve venous function in individuals with signs and symptoms of Chronic Venous Insufficiency (CVI), such as heavy, aching, or restless legs, and leg swelling.

---

Q: How does Centellase work?

A: The active components in Centellase, primarily triterpenes like asiaticoside, are believed to work in several ways. They may help to stabilize the walls of blood vessels, improving the strength and tone of veins and capillaries. This action is beneficial for conditions like Chronic Venous Insufficiency. Additionally, these components are thought to help stimulate the synthesis of collagen, which is a key protein in skin and connective tissue repair, promoting wound healing and scar maturation.

---

Q: What are the common side effects of Centellase?

A: Centellase is generally well-tolerated. The most common side effects are usually mild and may include:

• Gastrointestinal issues, such as stomach upset or nausea.
• Allergic skin reactions, such as rash or itching.

If you experience a severe allergic reaction (e.g., difficulty breathing, swelling of the face, tongue, or throat) or any persistent or bothersome side effects, you should consult a healthcare professional.

---

Q: Can Centellase be used during pregnancy or breastfeeding?

A: There is limited clinical data on the use of Centellase in pregnant or breastfeeding individuals. Therefore, it is generally recommended to avoid using Centellase during pregnancy or while breastfeeding unless specifically advised and monitored by a healthcare professional. A doctor can weigh the potential benefits against the possible risks.

---

Q: Can Centellase interact with other medications?

A: While significant drug interactions are not commonly reported, Centellase may potentially affect other medications. For instance, due to its possible effect on the liver, there is a theoretical risk of interaction with drugs that are also metabolized by the liver, such as certain sedatives or drugs that affect blood clotting. It is essential to inform your doctor or pharmacist about all other medications, supplements, and herbal products you are currently taking before starting Centellase.

The required storage and disposal instructions for Centellase are formally defined in regulatory documentation to ensure the stability of the active Centella asiatica extract.

Storage Component	Official Requirement
Temperature	Store below 30 C (86°F) and do not freeze.
Protection	Keep protected from direct light and moisture.
Container	Store in the original container and keep it tightly closed after use.
Child Safety	Keep out of the sight and reach of children (a mandatory safety requirement).
Disposal	Do not discard the medicine via wastewater or household trash. Dispose of unused or expired product according to local regulations or designated take-back programs.